News & Updates

Show Multimedia Only

CONFIDENCE supports simultaneous MR, SGLT2 inhibition in CKD and T2D

20 Jun 2025 by

The phase II CONFIDENCE* trial shows the benefit of dual therapy with the selective ns-MRA** finerenone and the SGLT2i** empagliflozin vs either agent alone in individuals with chronic kidney disease (CKD) and type 2 diabetes (T2D).

CONFIDENCE supports simultaneous MR, SGLT2 inhibition in CKD and T2D

20 Jun 2025

Cabozantinib plus atezolizumab improves PFS in mCRPC after progression on ARPI

20 Jun 2025

In the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with extrapelvic soft-tissue metastases that has progressed on an androgen receptor pathway inhibitor (ARPI), the combination of cabozantinib plus atezolizumab appears to prolong progression-free survival (PFS), according to data from the open-label phase 3 CONTACT-02 trial.

Cabozantinib plus atezolizumab improves PFS in mCRPC after progression on ARPI

20 Jun 2025

Long-term odevixibat shows sustained benefits in ALGS

20 Jun 2025 by

Long-term treatment with odevixibat led to sustained improvements in pruritus scores and reductions in serum bile acid (sBA) levels among patients with Alagille syndrome (ALGS), based on a pooled analysis of the phase III ASSERT and ASSERT-EXT studies presented at ESPGHAN 2025.

Long-term odevixibat shows sustained benefits in ALGS

20 Jun 2025

Lower KCCQ-12 scores predict death in outpatient HF care

19 Jun 2025

During outpatient heart failure (HF) care, patients with lower scores in the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) are at greater risk of hospitalizations and mortality, suggests a study. Moreover, those with scores <25 appear to have the highest risk.

Lower KCCQ-12 scores predict death in outpatient HF care

19 Jun 2025

How does finerenone fare among DKD patients in real life?

19 Jun 2025 by

In patients with chronic kidney disease and type 2 diabetes who have not been previously treated with any mineralocorticoid receptor antagonist (MRA), the use of finerenone results in marked reductions in albuminuria, reports a study presented at ERA 2025.

How does finerenone fare among DKD patients in real life?

19 Jun 2025

Abbreviated vs prolonged DAPT: Is shorter better for at-risk patients?

19 Jun 2025

One-month treatment with dual antiplatelet therapy (DAPT) results in similar adverse events and a reduction in total bleeding risk when compared with prolonged DAPT, a study has shown.

Abbreviated vs prolonged DAPT: Is shorter better for at-risk patients?

19 Jun 2025

Study ties energy drink intake to unhealthy lifestyle in young individuals

19 Jun 2025 by

A study presented at ESPGHAN 2025 reports that schoolchildren who consume energy drinks have unhealthier lifestyles and a different cardiovascular risk profile than their counterparts who do not or rarely consume energy drinks.

Study ties energy drink intake to unhealthy lifestyle in young individuals

19 Jun 2025

Semaglutide helps overweight schizophrenia patients on clozapine lose weight safely

19 Jun 2025

For patients with schizophrenia being treated with clozapine who have high BMI, semaglutide delivers weight-loss benefits without affecting psychotic symptoms or altering clozapine concentrations, according to the double-blind, phase II COaST study.

Semaglutide helps overweight schizophrenia patients on clozapine lose weight safely

19 Jun 2025

Sildenafil does not improve perinatal outcomes related to hypoxia during labour

18 Jun 2025

Treatment with sildenafil citrate during labour falls short of reducing the incidence of adverse perinatal outcomes potentially related to intrapartum hypoxia, according to a study.

Sildenafil does not improve perinatal outcomes related to hypoxia during labour

18 Jun 2025

Dual-target vaccine for flu, COVID-19 compares favourably with standalone comparators

18 Jun 2025 by

The investigational influenza–COVID-19 combination vaccine mRNA-1083 has demonstrated noninferiority to recommended standard-care flu and COVID-19 vaccines, with higher immune responses and an acceptable safety profile in adults at least 50 years of age, according to the results of a phase III trial.

Dual-target vaccine for flu, COVID-19 compares favourably with standalone comparators

18 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

CONFIDENCE supports simultaneous MR, SGLT2 inhibition in CKD and T2D

CONFIDENCE supports simultaneous MR, SGLT2 inhibition in CKD and T2D

Cabozantinib plus atezolizumab improves PFS in mCRPC after progression on ARPI

Cabozantinib plus atezolizumab improves PFS in mCRPC after progression on ARPI

Long-term odevixibat shows sustained benefits in ALGS

Long-term odevixibat shows sustained benefits in ALGS

Lower KCCQ-12 scores predict death in outpatient HF care

Lower KCCQ-12 scores predict death in outpatient HF care

How does finerenone fare among DKD patients in real life?

How does finerenone fare among DKD patients in real life?

Abbreviated vs prolonged DAPT: Is shorter better for at-risk patients?

Abbreviated vs prolonged DAPT: Is shorter better for at-risk patients?

Study ties energy drink intake to unhealthy lifestyle in young individuals

Study ties energy drink intake to unhealthy lifestyle in young individuals

Semaglutide helps overweight schizophrenia patients on clozapine lose weight safely

Semaglutide helps overweight schizophrenia patients on clozapine lose weight safely

Sildenafil does not improve perinatal outcomes related to hypoxia during labour

Sildenafil does not improve perinatal outcomes related to hypoxia during labour

Dual-target vaccine for flu, COVID-19 compares favourably with standalone comparators

Dual-target vaccine for flu, COVID-19 compares favourably with standalone comparators